uniQure Valuation Multiples

uniQure Overview

About uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Founded

2012

HQ

Employees

480

Website

uniqure.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $19M

EBITDA: ($177M)

EV

$540M

Valuation Multiples

Multiples.vc

Start free trial

uniQure Financials

uniQure reported last 12-month revenue of $19M and negative EBITDA of ($177M).

In the same LTM period, uniQure generated $16M in gross profit, ($177M) in EBITDA losses, and had net loss of ($204M).

uniQure P&L

In the most recent fiscal year, uniQure reported revenue of $16M and EBITDA of ($117M).

uniQure expects next 12-month revenue of XXX and NTM EBITDA of XXX

uniQure Stock Performance

uniQure has current market cap of $1B, and enterprise value of $540M.

uniQure's stock price is $17.58.

uniQure Valuation Multiples

uniQure trades at 28.9x EV/Revenue multiple, and (3.1x) EV/EBITDA.

uniQure Financial Valuation Multiples

As of April 18, 2026, uniQure has market cap of $1B and EV of $540M.

Equity research analysts estimate uniQure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

uniQure has a P/E ratio of (5.4x).

uniQure Margins & Growth Rates

uniQure's revenue in the last 12 month grew by 165%.

uniQure's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

uniQure's rule of 40 is (687%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

uniQure's rule of X is (606%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

uniQure Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

uniQure M&A Activity

uniQure acquired XXX companies to date.

Last acquisition by uniQure was on XXXXXXXX, XXXXX. uniQure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

uniQure Investment Activity

uniQure invested in XXX companies to date.

uniQure made its latest investment on XXXXXXXX, XXXXX. uniQure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).